Department of Gastroenterology, Nantong Haimen People's Hospital, Nantong, Jiangsu, 226100, People's Republic of China.
Department of gastroenterology, Traditional Chinese Medicine Hospital of Tongzhou District, Nantong, Jiangsu, 226300, People's Republic of China.
Int J Nanomedicine. 2024 Sep 30;19:10009-10021. doi: 10.2147/IJN.S483261. eCollection 2024.
Colorectal cancer (CRC) has become a significant global public health challenge, demanding immediate attention due to its high incidence and mortality rates. Regular CRC screening is essential for the early detection of precancerous lesions and CRC.
: We developed a novel surface-enhanced Raman scattering (SERS) analysis platform that employs high-throughput microarray chips as carriers and Au/SnO nanoring arrays (Au/SnO NRAs) as substrates. This platform utilizes an aptamer recognition-release strategy to achieve efficient and sensitive detection of protein tumor markers. In the detection process, the strong affinity and high specificity between the aptamer and the target protein result in competitive replacement of the SERS nanoprobes originally bound to the substrate surface. As a result, the SERS nanoprobes carrying Raman reporter genes are dislodged, leading to a reduction in the SERS signal intensity.
The platform demonstrated excellent detection performance, with rapid detection completed within 15 minutes and limits of detection (LOD) as low as 6.2×10 g/mL for hnRNP A1 and 6.51×10 g/mL for S100P. Clinical samples analyzed using the SERS platform showed high consistency with enzyme-linked immunosorbent assay (ELISA) results.
This platform offers strong support for the early detection, risk assessment, and treatment monitoring of colorectal cancer precancerous lesions, with broad potential for clinical applications.
结直肠癌(CRC)已成为一个重大的全球公共卫生挑战,由于其高发病率和死亡率,需要立即引起关注。定期进行 CRC 筛查对于早期发现癌前病变和 CRC 至关重要。
我们开发了一种新型的表面增强拉曼散射(SERS)分析平台,该平台使用高通量微阵列芯片作为载体,金/锡氧化物纳米环阵列(Au/SnO NRAs)作为基底。该平台利用适体识别-释放策略实现对蛋白质肿瘤标志物的高效灵敏检测。在检测过程中,由于适体与目标蛋白之间具有很强的亲和力和高度特异性,导致最初结合在基底表面的 SERS 纳米探针发生竞争性取代。因此,携带拉曼报告基因的 SERS 纳米探针被洗脱,导致 SERS 信号强度降低。
该平台表现出优异的检测性能,在 15 分钟内完成快速检测,检测限(LOD)对 hnRNP A1 低至 6.2×10 g/mL,对 S100P 低至 6.51×10 g/mL。使用 SERS 平台分析的临床样本与酶联免疫吸附测定(ELISA)结果高度一致。
该平台为结直肠癌癌前病变的早期检测、风险评估和治疗监测提供了有力支持,具有广泛的临床应用潜力。